iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $3.12 million. The enterprise value is $1.57 million.
Important Dates
The last earnings date was Monday, April 14, 2025, after market close.
| Earnings Date | Apr 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 2.50 million shares outstanding. The number of shares has increased by 57.25% in one year.
| Current Share Class | 2.50M |
| Shares Outstanding | 2.50M |
| Shares Change (YoY) | +57.25% |
| Shares Change (QoQ) | +64.64% |
| Owned by Insiders (%) | 4.48% |
| Owned by Institutions (%) | 3.45% |
| Float | 2.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.09 |
| Forward PS | n/a |
| PB Ratio | 0.62 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.17 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.62, with a Debt / Equity ratio of 0.09.
| Current Ratio | 0.62 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -57.84 |
Financial Efficiency
Return on equity (ROE) is -191.51% and return on invested capital (ROIC) is -117.33%.
| Return on Equity (ROE) | -191.51% |
| Return on Assets (ROA) | -63.21% |
| Return on Invested Capital (ROIC) | -117.33% |
| Return on Capital Employed (ROCE) | -355.55% |
| Revenue Per Employee | $387,130 |
| Profits Per Employee | -$520,742 |
| Employee Count | 24 |
| Asset Turnover | 0.74 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.50% in the last 52 weeks. The beta is 1.77, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.77 |
| 52-Week Price Change | -77.50% |
| 50-Day Moving Average | 1.42 |
| 200-Day Moving Average | 3.58 |
| Relative Strength Index (RSI) | 47.69 |
| Average Volume (20 Days) | 141,409 |
Short Selling Information
The latest short interest is 34,878, so 1.40% of the outstanding shares have been sold short.
| Short Interest | 34,878 |
| Short Previous Month | 79,731 |
| Short % of Shares Out | 1.40% |
| Short % of Float | 1.46% |
| Short Ratio (days to cover) | 0.58 |
Income Statement
In the last 12 months, iSpecimen had revenue of $9.29 million and -$12.50 million in losses. Loss per share was -$17.58.
| Revenue | 9.29M |
| Gross Profit | 3.99M |
| Operating Income | -12.73M |
| Pretax Income | -10.20M |
| Net Income | -12.50M |
| EBITDA | -12.47M |
| EBIT | -12.73M |
| Loss Per Share | -$17.58 |
Full Income StatementBalance Sheet
The company has $1.88 million in cash and $312,167 in debt, giving a net cash position of $1.57 million or $0.63 per share.
| Cash & Cash Equivalents | 1.88M |
| Total Debt | 312,167 |
| Net Cash | 1.57M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | 3.31M |
| Book Value Per Share | 1.95 |
| Working Capital | -2.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.26 million and capital expenditures -$56,546, giving a free cash flow of -$8.32 million.
| Operating Cash Flow | -8.26M |
| Capital Expenditures | -56,546 |
| Free Cash Flow | -8.32M |
| FCF Per Share | -$3.33 |
Full Cash Flow StatementMargins
Gross margin is 42.93%, with operating and profit margins of -136.99% and -134.51%.
| Gross Margin | 42.93% |
| Operating Margin | -136.99% |
| Pretax Margin | -134.51% |
| Profit Margin | -134.51% |
| EBITDA Margin | -134.22% |
| EBIT Margin | -136.99% |
| FCF Margin | n/a |